InterMune (FRA:IUX) 5-Year Yield-on-Cost % : 0.00 (As of Sep. 24, 2024)

View and export this data going back to . Start your Free Trial

What is InterMune 5-Year Yield-on-Cost %?

InterMune's yield on cost for the quarter that ended in Jun. 2014 was 0.00.

The historical rank and industry rank for InterMune's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:IUX's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.71
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of InterMune's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, InterMune's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InterMune's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where InterMune's 5-Year Yield-on-Cost % falls into.

InterMune 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of InterMune is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

InterMune (FRA:IUX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

InterMune 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of InterMune's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

InterMune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.intermune.com

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune Headlines

No Headlines